EU's CHMP recommends Pharming's Ruconest for HAE
This article was originally published in Scrip
Executive Summary
The EU's CHMP has recommended marketing authorisation of Pharming's C1 esterase inhibitor Ruconest (also known as Rhucin and conestat alfa) for the treatment of acute angioedema attacks in adult patients with hereditary angioedema (HAE).